ArticleHealthcare (Basel, Switzerland)2023
Hyperuricemia as a Risk Factor in Hypertension among Patients with Very High Cardiovascular Risk.
Article in Healthcare (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Antihyperuricemic Effect of Hawthorn Flavonoid Vitexin: LC-MS Analysis, Network Pharmacology, and In Vivo Verification of Molecular Mechanisms.Food science & nutrition · 2026Article
- Nonlinear Association of the Triglyceride-Glucose Index With Hyperuricemia Among Young Chinese Adults.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Associations Between a Surrogate Index of Insulin Resistance and Hyperuricemia in Young and Middle-Aged Patients With Type 2 Diabetes Mellitus.Journal of diabetes research · 2026Article
- Genome analysis of a newly isolated Lysinibacillus fusiformis-YC01 for biodegrading inosine and guanosine.Biodegradation · 2025Article
- Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2023 update.Cardiology journal · 2024Article
- Hyperuricemia - consequences of not initiating therapy. Benefits and drawbacks of treatment.Reumatologia · 2024Review
- Sex-Related Differences in the Prevalence of Classical, Non-Classical Risk Factors and Management of the Chronic Coronary Syndrome.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Hypertension remains a global threat to public health, affecting the worldwide population. It is one of the most common risk factors for cardiovascular disease. Today's treatments focus on creating a hypotensive effect. However, there is a constant search for additional factors to reduce the potential of developing hypertension complications. These factors may act as a parallel treatment target with a beneficial effect in specific populations. Some studies suggest that uric acid may be considered such a factor. This study investigated the potential effect of uric acid concentrations over 5 mg/dL on the incidence of hypertension complications among patients with very high cardiovascular risk. A total of 705 patients with hypertension and very high cardiovascular risk were selected and included in the analysis. The patients were divided and compared according to serum uric acid levels. The study showed a higher occurrence of heart failure (OR = 1.7898; CI: 1.2738-2.5147;
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.